

SUPPLEMENTAL AMENDMENT
U.S. Appl. No. 09/719,423

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended): A compound consisting of an insulin molecule covalently bound to 3, 3', 5' triiodothyronine, wherein the insulin molecule is covalently bound through an amide bond formed between an amine group on the insulin molecule and a carboxylic group, and the amine group is an ϵ -amino group of a lysine residue, or is the N-terminal amine group of a polypeptide chain of ~~[[an]]~~ the insulin.
2. (Previously Presented): A compound according to claim 1 in which the 3,3', 5' triiodothyronine is bound to a lysine residue of the insulin molecule.
3. (Previously Presented): A compound according to claim 1 in which the 3, 3', 5' triiodothyronine is bound to the B1 residue.
4. (Previously Presented): A compound according to any preceding claim in which the insulin is human insulin.
5. (Previously Presented): A compound according to claim 1 for use in a method of treatment of the human or animal body.
6. (Previously Presented): A composition comprising a compound according to claim 1 and a carrier.
7. (Original): A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.
8. (Cancelled).

SUPPLEMENTAL AMENDMENT
U.S. Appln. No. 09/719,423

9. (Cancelled).

10. (Previously Presented): A composition comprising a compound according to claim 3 and a carrier.

11. (Previously Presented): A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.

12. (Currently Amended): A method of treatment of a human or other animal by insulin [[replacment] replacement therapy in which a compound according to claim 1 is administered to the human or other animal.

13. (Previously Presented): A method of treatment of a human or other animal by insulin replacement therapy in which a compound according to claim 3 is administered to the human or other animal.

14. (Previously Presented): A method according to claim 12 or claim 13 in which the human or other animal is suffering from diabetes.

15. (Previously Presented): A method according to claim 12 or claim 13 in which the compound is administered into the circulation of the said human or animal.

16. (Previously Presented): A compound according to claim 3 in which the B1 lysine residue is Phe.

17. (Previously Presented): A compound according to claim 2 in which the insulin is human insulin.

18. (Previously Presented): A compound according to claim 3 in which the insulin is human insulin.